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Abstract: Pain therapy, the most widely spread disorder, tends more as other diseases, to administration of drug 
molecules targeted to the affected tissue at the right dose, or to the patient or patient groups (personalized medicine). A 
decisive determinant of this strategy is the genetic one, which is to some extent the basis of the variability of 
pharmacokinetic and pharmacodynamic response to analgesics in the patient population. The differences in action and 
response to analgesics are due in these cases to hyperfunctional or nonfunctional uni-nucleotide gene polymorphisms 
encoding enzyme-modified transport proteins or receptors involved in the biotransformation and dynamics of analgesics. 




Pain, especially chronic, affects a large number of patients and can become itself by its persistence a self-contained 
disease with significant costs to society and varying degrees of disability for patients with professional, social, and family 
consequences. Population studies conducted in the United States have shown that the number of prescriptions for painful 
sufferings in 20 years (1991-2011) has risen dramatically from 76 million to 219 million (Reuben, 2015). The approach 
over the past two decades to combat both chronic and acute pain on genetic basis, justifies the hopes of the effectiveness 
of this type of therapy and the reduction of costs allocated by the population and the state for analgesics. One of the open 
pathways for this is represented by the therapeutic transfer of viral or non-viral vectors, RNA or DNA segments encoding 
antinociceptive factors involved in the natural pain control mechanism (endogenous opioids, neurotransmitters, 
neurotrophins, growth factors, immunomodulators) which injected into target tissues or peripheral tissues, are conveyed 
by natural transport systems in the neurons and glia of the spinal nerve networks responsible for pain (Goins, 2012; 
Kibaly, 2016). The second therapeutical pathway on genetic basis is personalized therapy not only of chronic and acute 
pain but also of other diseases in which it has proved effective (diabetes, cancer, hypertension, tuberculosis, etc.). 
Successful treatment of pain or other suffering in certain patient groups, with certain drug molecules and in personalized 
doses, is part of the new concept of layered or personalized medicine (genomic medicine). Initially, pharmacogenetics 
deciphered individual allele-based pathological abnormalities of perceptions for painful sensitivity due to presence of 
some restricted gene polymorphisms (specific and typically rare in the population such as certain familial hereditary 
diseases). Then, as the genotyping acquisitions proceeded, the localization and other genes continued to decrypt the 
causes of variability in the patient's response to different classes of analgesics, from optimal response to those of 
unexplained failure of the same therapies with the same doses. Personalization of genotyping means the separation of 
patients on well-tailored therapeutic groups based on the results of genetic tests, regarding the identification and 
evaluation of interindividual allelic variability of single nucleotide polymorphisms (SNP) polymorphisms present in 
genes. This is reflected in patients' response to medication. Personalized medicine is important both for effective pain 
therapy in adults and the pediatric population (Schiavone, 2017). In addition to the known rarely genetic major defects 
family inherited, referred above, genetic influences in the population with painful disorders contribute synergistically or 
antagonistically to the phenotypic expression of the response to analgesic therapy. Research shows that although in the 
mass of the population a frequent situation is the mutual canceling of polymorphisms and genetic effects, the frequency of 
the functional mutant gene variants involved in the pharmacokinetics and pharmacodynamics of analgesics is still 
between 10-50% (Lotsch, 2009). This makes that the genetic differences with an impact on patients' response to 
analgesics, especially first-line drugs like opioids, to be increasingly taken into account when choosing a strategy for 
analgesic therapy, a motivated option otherwise by observations from medical practice. It is known, for example, that the 
success rate for morphine is only 65% at the same dose and affection (Mogil, 1999). The lack of favorable response to 
opioids for the other 35% of patients is based on both genetic and cumulative contribution of epigenetic factors, both of 
which being still insufficiently investigated and evaluated. It is also proven that the human population is divided into 
morphino-sensitive and morphino-insensitive individuals (Buchsbaum, 1977) and that there is a demonstrated 
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concordance between the rate of identical pain-related features in monozygotic as opposed to dizygotic brothers (Martin, 
1997). On the other hand, other examples show that, depending on the target receptors, men's analgesia is mu-opioid (men 
respond better to mu-receptor opioids), whereas in women analgesia is kappa-opioid, and stress analgesia is mediated in 
men by glutamate and in women through non-glutamic mechanism. Taking into account the differences, the 
administration of the targeted drug to the affected individual and tissue ("magic bullet") and no adverse effects is no 
longer far away. Blakey (2011) affirmation remains valid: "Each prescription written constitutes an excursion into the 
unknown that is fundamental to the balance of risk or benefit in medicine. Will the patient respond fully, partially or not 
at all? Will there be unacceptable or even life-threatening adverse effects? ". It is true that for the time being, only 
relatively small groups of patients can benefit from genetically guided therapy, but the basis for expanding this concept is 
now being opened by decoding the human genome, reducing the cost of DNA sequencing associated with increasing the 
number of accessible genetic tests that can select the appropriate drug molecule in the appropriate patient at the 
appropriate doses and times. One of the most widely used predictive pharmacological tests (first approved in the US and 
the EU) is AmpliChip CYP450 on DNA microarrays with rapid scanning of thousands of markers that identify the 
polymorphisms of the CYP2D6 and CYP2C19 genes, principally responsible for metabolic liver enzymes, with an 
important modulating role of drug response (Covic, 2012).      
 
GENETIC MODULATION OF ANALGESICS PHARMACOKINETICS 
 
The pharmacokinetics of analgesics includes a sequence of treatments to which all the drug substances in the body are 
subjected: absorption (bioavailability), biotransformation (metabolism), transport, distribution and excretion of the 
administered substances (Goodman Gilman, 1992). 
 
INFLUENCE OF THE GENETIC FACTOR  
IN THE ANALGESICS METABOLISATION 
 
A crucial process with significant impact in the treatment of pain is the metabolisation of analgesics that is performed in 
two phases (I and II). Phase I involves oxidation, reduction and hydrolysis, processes that can result in inactive, weakly 
active or more active metabolites than the primary drug. In the phase II, are taken place combinations/conjugations of the 
metabolites with a substrate (glucuronoconjugation, glutamino- and sulfoconjugation, acetylation or methylation) are 
carried out in the presence of catalytic enzymes: N-acetyltransferase, UDP-glucuronosyltransferase (GGT) and glutathion 
S-transferase (GSTs). Analgesic drugs commonly used in medical practice include opioid substances (morphine and 
morphinomimetics) and non-opioid substances. The most commonly used of these are antiepileptic/non-steroidal anti-
inflammatory NSAIDs. Their action is inhibitory to cyclooxygenase-COX enzyme synthesizing prostaglandin (PG) 
enzymes with algic and/or inflammatory activity (especially PG2). NSAIDs commonly used are non-selective COX or 
with reduced selective inhibitors (diclofenac), COX-1 selective inhibitors (ibuprofen, naproxen, acetyl salicylic acid, 
indomethacin) and selective COX-2 inhibitors (celecoxib, parecoxib, etoricoxib). Non-opioid analgesics include also 
serotonin (triptans) and neuroleptics (co-analgesics) agonists such as anticonvulsants and antidepressants. Many 
substances used in pharmacological therapeutics and implicitly in pain therapy are metabolised in Phase I by oxidation by 
cytochrome P450 hemoprotein enzymes superfamily, which determined the focus of pharmacogenomics research on 
genes responsible for P450 synthesis. Some of the enzymes in this family process oxidative the molecules involved in 
pain mechanisms, both endogenous molecules synthesized by the body such as pain mediators (substance P, serotonin, 
histamine, cytokines, bradykinins, prostaglandin E2) or pain suppressors (own opioids) and also exogenes (analgesic and 
co-analgesic drugs). For the synthesis of these protein-enzymes are responsible 57 functional cytochrome P (CYP) genes 
and 58 non-functional CYP genes (Muralidharan, 2011). Mutations by single nucleotide polymorphism (SNP) 
substitutions or deletions occurring in the genes responsible for the synthesis of P450 enzymes induce changes in 
metabolism (biotransformations) of administered analgesics. Thus, the decrease in enzyme metabolism of analgesics 
prolongs their effects by prolonging their duration of action and delaying elimination from the body (eg NSAIDs). Other 
analgesic drugs (codeine, tramadol, metamizole, parecoxib, tilidine) increase their action over the pain even through 
catabolites resulting from metabolisation. Genomic polymorphic variants with a proven and currently proven role in drug 
metabolism are those responsible for the synthesis of CYP1A2, CYP2D6, CYP2C9, CYP3A4, CYP2E1, CYP2A6 
enzymes. The genes responsible for the synthesis of mentioned enzymes may have each their own distinct sub-variants. 
For example, the synthetizing CYP2D6 gene of the metabolizing enzyme CYP2D6 has over 80 polymorphic sub-variants 
corresponding to extended varieties of enzymatically expressed phenotypes among the population. Numerous DNA 
sequencing meta-analyzes associated with clinical data have eventually led to the acceptance of the possible classification 
of SNP polymorphisms in carrier populations among various populations of the globe in 4 groups depending on the 
metabolic effects of the synthesized enzymes. It has been agreed to choose as the metabolic behavioral prototype the 
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CYP2D6 gene responsible for expression of the following variants of enzymatic phenotypes: a) poor metabolic action 
(PM) enzymes due to the presence of 2 deficiency alleles with deficit in analgesic hydroxylation; b) intermediary action 
(IM) with a non-functional allele; c) extensive action (EM) with a functional allele and d) ultrafast action (UM) with two 
functional alleles. The existence and level of action of citocrom P450 in the patients mass with pain has a particular 
clinical and therapeutic significance since the predominant coding of one or other of the enzymatic variants enumerated 
above depends on the variability of the degree of pain abolition at the same usual dosage of the analgesic substance. 
Substances carrying allelic variants that synthesize weakly-metabolizing (PM) enzymes may, for example, exhibit low 
oxidative processing, persistent high plasma concentrations of the administered analgesic and slow elimination with good 
analgesic effect but which can induce by the high levels also undesirable consequences (eg. adverse effects, sometimes 
risky). On the contrary, the individuals at the other extremity, with duplications or gene multiplications in the UM 
metabolisation position type, can induce a rapid hepatic metabolisation of the analgesic substance, resulting in sub-
therapeutic, inefficient plasma levels. The CYP2D6 prototype gene influences the pharmacokinetics of a large number of 
drug substances, approximately 25% of commonly used drugs, including opioid, anti-emetic, antiarrhythmic, 
antipsychotic (Zhou, 2009). At the same time, the distribution of over 100 known functional gene variants of the above-
mentioned CYP450 enzymes is important. From this point of view, there are significant differences in the frequency of 
variant carriers depending on their belonging to different ethnic groups, which should be taken into account in the 
medical practice in order to obtain the maximum therapeutic efficiency, while avoiding the risk of toxic accidents. Thus, a 
significant percentage of the Arabian and Ethiopian populations (29%) are carriers SNP polymorphic variants of the UM 
CYP2D6 gene type, whereas 7-10% of the Caucasian populations are affected by the presence of the autosomal recessive 
character of the CYP2D6 non-functional allele, while in Asians their presence is only 0.5%. Other examples are offered 
by the CYP2D4 variant, which has a frequency of 20% in Caucasians but is absent in the Chinese. Also, CYP2D6*-10 is 
specific to Asians, and CYP2D6*-45 and 46 variants are characteristic of African populations (Stamer, 2010). On the 
other hand, interindividual genetic variability also involves other types of related changes in patient behavior towards 
certain drug molecules. For example, in carriers with functional deficiency of the CYP2D6 gene with poor enzyme 
variant (PM), the beneficial effect of protection against opioid dependence is proven (Tyndale, 1997). 
 
MODULATION OF METABOLIC PHASES I AND II OF OPIOID ANALGESICS 
(CODEINE, TRAMADOL, MORPHINE) 
 
In metabolic phase I, codeine (methylmorphine) is strongly transformed by cytochrome P450 CYP2D6 isoenzyme into 
codeine-6-glucuronide intermediate products + nor-codeine (together with 83% from codeine) and morphine-6-
glucuronide-M6G (6%). The analgesic effect of codeine is given by the M6G metabolite which has a 200-fold higher 
affinity for opioid miu receptors compared to morphine. The CYP2D6 enzyme is known to have many functional 
isoforms corresponding to the polymorphic gene variants which respond by their synthesis and functionally evidenced by 
the metabolic enzyme decrease, increase or metabolic-enzymatic inactivity on codeine. Thus, enriched gene-type 
polymorphic enriched versions of EM for CYP2D6 may present exaggerated effects at common doses of codeine, with 
predisposition to intoxication or even life-threatening by potentiating the side effects of the M6G metabolite (eg 
depression of breathing) being reported deaths in this way (Ciskowski, 2009). A high SNP gene variability is from this 
point of view the Caucasian populations in which treatment of pain with 60 mg of codeine that should reduce pain 
intensity by 50% finishes in 1 of 7 patients with failure or toxicity (Lotsch, 2009). Moreover, in such cases, adverse 
reactions may precipitate in genetically uninvestigated patients to who are filled opioids with non-opioid analgesics or in 
individuals with associated deficiencies in the excretion of metabolites (eg renal impairment). Other isoforms with 
metabolic action on codeine are CYP3A and UGT2B7. A codeine-like behavior is presented by tramadol (an opioid 
metabolised by the CYP2D6 enzyme), by its O-desmethyl-tramadol derivative (O-DSMT) derivative, which in turn has 
an affinity for the miu opioid receptors of 200 times higher than tramadol (Stamer 2003, 2007). Patients carrying PM 
variants with poor enzyme activity on the tramadol substrate (eg CYP2D6*10 homozygous Chinese) require high doses 
to achieve the analgesic effect (at risk for adverse effects in undetected genetically patients), unlike those who are carriers 
of at least one wild allele (Wang, 2006). Also, in carriers of gene-rich variants with extensive metabolism, the increase of 
O-DSMT favors the risk of side effects. Regarding the phase II metabolisation of analgesics represented by conjugation, 
an increasing interest has been shown since 1990 on the UGT enzyme (uridine diphospho- glucuronosyl-transferase) with 
the UGT2B7 isoform (from UGT-A1-10, UGT2B-4, 7,10,11,15,17,28 family). The isoform UGT2B7 is a special enzyme 
that has demonstrated strong glucuronidation actions of analgesic drugs such as morphine, codeine, buprenorphine, 
fluribiprofen, nonsteroidal anti-inflammatory drugs and anticonvulsants. It catabolizes morphine in two compounds with 
opposite effects: morphine-6-glucuronide (M6G) with analgesic effects (and with a 42-fold more expanding than 
morphine variability coeficient) and morphine-3-glucuronide (M3G-70%) with antianalgesic, excitatory effects. Various 
gene polymorphisms (SNPs) of the UGT2B7 gene in the nontranslational region induce morphine-derived metabolite 
alterations, e.g., M6G decrease, while UGT2B7*2/2 variant combined with the CYP2D6 enzyme has reversed effects. 
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CONTRIBUTION OF GENE VARIABILITY IN THE METABOLISM OF NON-OPIOID 
ANALGESICS 
 
In pain-relieving analgesic pharmacology, not only opioids, but also non-opioid drugs have an important place to combat 
chronic pain, post-surgery pain, or frequently associated with opioids in the treatment of acute postoperative pain, or in 
addition to opioid medication in major surgery. They complete the analgesic action, reduce the side effects of opioids by 
reducing their doses and reduce the risk of opioid addiction. There is a certain genetic influence on the effectiveness of 
non-opioid analgesics, a class of drugs that include: synthetic NSAIDs and some neuroleptics, antiemetics, 
antiarrhythmics or serotonin reuptake inhibitors. Thus, NSAIDs contribute to pain relief by inhibiting CYP2C9, CYP2C8 
and CYP2C19 genes responsible for the formation of catabolic enzymes. Contributions of genetics to modification of 
inhibitory actions on genes and enzymes were first suggested by highlighting in some experimental animals, but also in 
some patients, a high degree of sensitivity to NSAIDs or paracetamol, while others, on the contrary, found the presence of 
increased resistance to this therapy. In recent years, it has been shown that response differences are due to the variability 
of action (gene-dependent) of metabolizing enzymes on the drug substrate. For example, it is now known that the 
synthesis of enzymes which metabolise synthesis NSAIDs (diclofenac, ibuprofen, naproxen, piroxicam, celecoxib, 
parecoxib, etoricoxib, valdecoxib) significantly responds to the CYP2C9 gene (33 sub-variants), CYP2C8 and CYP2C19. 
The existence to polymorphic genic variants carriers of gene CYP2C9 PM type (metabolic / enzymatic weak effect on 
NSAIDs) allows to CYP2C9*3 homozygotes slowing down the elimination of the analgesic (COX-1 and 2 inhibitors) and 
consequently increase of their concentration in plasma over 2 fold compared to CYP2C9*1/1 wild-type carriers (Tang, 
2001; Stamer, 2007). Delayed excretion of NSAIDs in CYP2C9*3 allele carriers is associated with an increase in 
pharmacodynamic activity with significant clinical effects but which not exclude careful monitoring of the risk of adverse 
effects on these substances. Catabolism of other substances used to combat pain in association with opioids (with the 
advantage of lowering their dosages especially in the treatment of chronic pain) such as co-analgesics represented by 
adjuvants neuroleptics such as antidepressants (dextromorphan, trimipramine or paroxetine), antipsychotics (haloperidol), 
antiemetics (metoclopramide) or antiarrhythmics (amiodarone) are made by enzymes synthesized under the control of the 
CYP2D6 gene, which also controls opioid metabolism. For example, carriers of the CYP2D6 polymorphic (SNP) gene 
variant with a reduced degree of synthesis (PM type) of the metabolizing isoenzyme exhibit high exposure to the drug by 
slowing metabolism associated with a risk of adverse reactions. In contrast, duplicates of the CYP2D6 gene with ultra-
fast enzyme metabolism (UM type) of antidepressants or antipsychotics can result in ineffective sub-therapeutic 
concentrations (Kirchheiner-2003, 2004). Antidepressants used in the treatment of chronic pain are substrates for other 
genes by the enzymes they synthesize, such as the CYP2C19 and ABCB1 genes. 
 
GENETIC INFLUENCE OF THE ANALGESICS TRANSPORT 
 
An important role in the pharmacokinetics of analgesics is represented by the drug-carrier molecules family in brain 
regions with key roles in the central mechanisms of pain. Most transporters are glycoproteins that modulate the hemato-
encephalic and neuronal transmembrane passage, and finally the intracellular concentration of the therapeutic molecules. 
One of the most well-known transporters group is the ABC family with 7 subfamilies and 49 members (Muralidharan, 
2011; Mercer, 2011), the most studied transporter being B1 glycoprotein P (P-gp). The P-gp transporter is encoded by the 
ABC B1 gene and acts as a transmembrane pump for the active transport of some drug molecules, implicitly analgesic. It 
has over 50 mutational SNP variants with numerous polymorphisms (by insertions / deletions) identified in the ABC B1 
gene that increase or decrease the concentration of analgesics in the brain by their transport with variable velocity through 
the blood-brain barrier. In this way, for example, modifications of the polymorphic encoded SNP positions of the ABCB1 
gene shows in both animal and clinical experiments in cancer patients treated with morphine, significant associations with 
the variability of analgesia and the reduction of adverse effects (Fujita, 2010). The P-gp transporter mediates the effects 
of opioids and antidepressants through its structural functional variants genetically coded. It has thus been shown in 
heroin-dependent patients undergoing methadone replacement therapy that the doses may be reduced to carrier of 
ABCB1-2435 C>T variants that decrease the expression of the P-gp transporter resulting in slowing of the methadone 
flow out of the brain . The transport also modulates in this way methadone-induced analgesia, as evidence of increased 
anti-antalgic effects following the pharmacological blockade of the P-gp transporter (Coller, 2006; Lotsch, 2009; Mercer, 
2011). SNP gene variants responsible for carrier synthesis modulate the variability of patient response to other molecules 
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GENETIC MODULATION OF PHARMACODYNAMIC ACTION OF ANALGESICS 
 
The biochemical and physiological effects, as well as the mechanisms of action of the analgesics, are part of their 
pharmacodynamics and are influenced by the variability of genotypes in the population mass as well as the 
pharmacokinetic processes mentioned above. The decisive factor of the pharmacodynamics of analgesics depends on the 
ability and their effectiveness of coupling to neurons receptors in the spinal and cerebral target areas, with a role in pain 
perception. Poor binding on membrane receptors or low number of active receptors induce poor and unsatisfactory 
therapeutic effects on pain. Receptors, as protein structures, are genetically encoded, in the first line of the analgesic 
efficacy being the opioid receptors: miu, delta, kappa, epsilon and the orphan receptor FQ (nociceptin). All of mentioned 
opioid receptors manifest their actions by modulating G protein (pGm) in their structure, in this case the inhibiting variant 
of protein G (Gi) with the reduction of AMPc formation. The OPRM1 gene responsible for the encoding of the opioid 
miu receptor is highly SNP polymorphic, mutant variants being due either to alteration of the extracellular receptor 
domains or to the intracellular neurons (Shabalina, 2009). In the first case, was identify the decrease of the extracellular 
glycosylation site of the protein-miu receptor (replacement aspartate with asparagine at position 40) with reduction of the 
analgesic effects of the opioids (see note I). In the second case, is better known the OPRM1 mutant gene variant which 
affects the 3rd intracellular loop of the receptor followed by cascade events: decrease in G protein binding capacity, 
decrease in receptor signaling capacity and decrease in therapeutic effects or even inefficiency of the analgesic. This 
mutation affects precisely those cerebral neuronal areas densely populated by miu opioid receptors involved in natural 
pain control and stimulation of reward behavior, associated in the same time with important participations in the 
mechanisms of perception and pain feeling: the somatosensory cortical area I and II, the anterior cingulated cortex, the 
posterior islet cortex and the accumbens nucleus. The patient carriers of OPRM1 gene mutation need to reduce or 
suppress pain high doses of opioid analgesics: morphine, M6G, alfentanil, methadone (Oertel, 2009). The alteration of the 
pharmacodynamic intimate mechanism is related to two key factors of miu neuronal receptor function: (1) G-protein - 
kinase receptors (GRK)  on surface neuronal membrane regulating Gi protein by phosphorylation and 2) protein G - K+ 
rectifying channels (GIRK), couples factors being primary post-synaptic effectors in central nervous system neurons. In 
the first case (GRK), mutant coding of modulators signal proteins arrestin beta-1 and 2 block the action of the Gi protein 
by inducing desensitization (lack of activation) of the phosphorylated miu opioid receptor (Ferguson, 1996). In the second 
case (GIRK), normally the GIRK ionic channels present in the heart (involved in the mechanism of cardiac pain), spinal 
cord, cerebral zones activated by coupling with the G protein opens, followed by an influx of K+ ions from the 
extracellular space in the cytoplasm, activating in turn the miu opioid receptors that induce analgesia by blocking the 
transmission of pain. In contrast, in carriers of ion channels genetically modified GIRK, mutations in the intracellular 
domain of GIRK decrease their sensitivity for the Gi receptor protein. Under these conditions, the binding of the Gi 
protein to a neuronal receptor ligand (the ligands may be for miu receptors and nociceptin FQ receptors or for muscarinic 
receptors, adrenergic alpha2, serotonin 1A, cannabinoid, adenosine 1A), results in the reduction of K+ inside the cell, to 
which is added the depression of N-type Ca2+ channels, which ultimately induces opioid receptor desensitization 
(Nishizawa, 2014). GIRK1 channels (encoded by the KCVJ3 gene) participate in opioid analgesia (Marker, 2004), and 
GIRK2 channels (CKNJ6 gene) contribute to modulation of opioid-induced tolerance (Saland, 2008). GIRK1,2 and 
GIRK3 (encoded by the KCNJ9 gene) strongly modulate painful sensitivity, gene knockout mice developing hyperalgesia 
(Marker, 2004; Smith, 2008). The GIRK2 and GIRK6 ion channels are involved in inflammation and allodynia by 
lowering the excitability threshold and increasing pain sensitivity (Eijkelkamp, 2009). Two of the SNP mutant variants 
(Cs2835859) of the CKNJ6 and KCNJ9 genes have recently been identified as being responsible for the analgesic and 
pain sensitivity associated with the predisposition for nicotine, alcohol and cocaine dependence and can serve as useful 
markers in medical practice (Nishizawa, 2014). Desensitization of neuronal opioid receptors promotes the occurrence and 
installation of pain, primarily being targeted bulbar neurons from locus coeruleus area and cerebrospinal gray substance 
from the brainstem, major inhibitory areas in ascending pain transmission through spinal tangles to the thalamus and 




The pharmacokinetic and pharmacodynamic advantages of analgesic pain therapy based on 
pharmacogenomic molecular mechanisms are primarily due to the increase in efficiency by 
individualization treatment under the conditions of dose reduction, the ideal of any drug therapy 
(it is known that "in the usual classical treatment, patients take biger doses for smaller effects "-
Stamer, 2007). In addition, is followed the avoidance of adverse side effects and toxicity 
(100,000/year deaths in the USA by adverse effects), reducing the risk of addiction, avoiding the 
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loss of time to maximize efficacy doses and appropriate drug associations, avoiding 
polypragmasia and drug interactions which can amplify (or block) the metabolic effects of 
enzymes and especially the occurrence of adverse effects in particular in fragile individuals such 
as elderly with multiple sufferings and associated therapies or young children. Since the 
phenotype of pain and response to treatment are also influenced by epigenetic factors 
(environmental factors, lifestyle, diseases and associated medications), in the near future, it will 
be more accurately highlighted how and where these factors induce subtle changes summed up in 
the genome of individuals. Today the recent acquisitions, as well as the benefits of 
pharmacogenomics, widen the possibility of applying these data and results to pain management 
strategies in order to maximize the efficiency gains on this basis. It is true that there are complex 
difficulties due to the redundancy and pleiotropism characteristic of the biological systems, 
which require time to solve and that the therapy of acute and chronic pain can not yet be 
personalized satisfactorily (depending on the patient's genotype) for large populations. Many 
times, only the accentuated adverse effects or the failure of the therapy can direct the physician's 
prediction to a genetic motivation. But predictive analgesic therapy, guided and genetically 
individualized, remains for the very near future the most effective strategic option for well-
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